MDGL
Price
$325.00
Change
+$0.29 (+0.09%)
Updated
Jan 23, 10:33 AM (EDT)
Capitalization
7.08B
34 days until earnings call
SLS
Price
$0.95
Change
-$0.19 (-16.67%)
Updated
Jan 23, 12:52 PM (EDT)
Capitalization
80.24M
56 days until earnings call
Ad is loading...

MDGL vs SLS

Header iconMDGL vs SLS Comparison
Open Charts MDGL vs SLSBanner chart's image
Madrigal Pharmaceuticals
Price$325.00
Change+$0.29 (+0.09%)
Volume$200
Capitalization7.08B
SELLAS Life Sciences Group
Price$0.95
Change-$0.19 (-16.67%)
Volume$17.22K
Capitalization80.24M
MDGL vs SLS Comparison Chart
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDGL vs. SLS commentary
Jan 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a Hold and SLS is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 23, 2025
Stock price -- (MDGL: $324.71 vs. SLS: $1.14)
Brand notoriety: MDGL and SLS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 92% vs. SLS: 96%
Market capitalization -- MDGL: $7.08B vs. SLS: $80.24M
MDGL [@Biotechnology] is valued at $7.08B. SLS’s [@Biotechnology] market capitalization is $80.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 1 FA rating(s) are green whileSLS’s FA Score has 0 green FA rating(s).

  • MDGL’s FA Score: 1 green, 4 red.
  • SLS’s FA Score: 0 green, 5 red.
According to our system of comparison, MDGL is a better buy in the long-term than SLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 3 TA indicator(s) are bullish while SLS’s TA Score has 3 bullish TA indicator(s).

  • MDGL’s TA Score: 3 bullish, 5 bearish.
  • SLS’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, SLS is a better buy in the short-term than MDGL.

Price Growth

MDGL (@Biotechnology) experienced а +18.33% price change this week, while SLS (@Biotechnology) price change was +17.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.70%. For the same industry, the average monthly price growth was +2.32%, and the average quarterly price growth was -2.48%.

Reported Earning Dates

MDGL is expected to report earnings on May 13, 2025.

SLS is expected to report earnings on May 14, 2025.

Industries' Descriptions

@Biotechnology (+1.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($7.08B) has a higher market cap than SLS($80.2M). SLS YTD gains are higher at: 9.615 vs. MDGL (5.231). SLS has higher annual earnings (EBITDA): -32.77M vs. MDGL (-502.65M). MDGL has more cash in the bank: 999M vs. SLS (21M). SLS has less debt than MDGL: SLS (576K) vs MDGL (119M). MDGL has higher revenues than SLS: MDGL (76.8M) vs SLS (0).
MDGLSLSMDGL / SLS
Capitalization7.08B80.2M8,830%
EBITDA-502.65M-32.77M1,534%
Gain YTD5.2319.61554%
P/E RatioN/AN/A-
Revenue76.8M0-
Total Cash999M21M4,757%
Total Debt119M576K20,660%
FUNDAMENTALS RATINGS
MDGL vs SLS: Fundamental Ratings
MDGL
SLS
OUTLOOK RATING
1..100
2322
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
27100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
4038
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLS's Valuation (57) in the Biotechnology industry is in the same range as MDGL (70) in the Pharmaceuticals Other industry. This means that SLS’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (27) in the Pharmaceuticals Other industry is significantly better than the same rating for SLS (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than SLS’s over the last 12 months.

MDGL's SMR Rating (99) in the Pharmaceuticals Other industry is in the same range as SLS (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to SLS’s over the last 12 months.

SLS's Price Growth Rating (38) in the Biotechnology industry is in the same range as MDGL (40) in the Pharmaceuticals Other industry. This means that SLS’s stock grew similarly to MDGL’s over the last 12 months.

SLS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that SLS’s stock grew similarly to MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLSLS
RSI
ODDS (%)
Bearish Trend 16 days ago
73%
N/A
Stochastic
ODDS (%)
Bearish Trend 16 days ago
90%
Bearish Trend 16 days ago
86%
Momentum
ODDS (%)
Bullish Trend 16 days ago
76%
Bullish Trend 16 days ago
90%
MACD
ODDS (%)
Bullish Trend 16 days ago
81%
Bullish Trend 16 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 16 days ago
76%
Bearish Trend 16 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 16 days ago
76%
Bearish Trend 16 days ago
89%
Advances
ODDS (%)
Bullish Trend 16 days ago
78%
Bullish Trend 21 days ago
85%
Declines
ODDS (%)
Bearish Trend 24 days ago
81%
Bearish Trend 16 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 16 days ago
71%
Bearish Trend 16 days ago
89%
Aroon
ODDS (%)
Bearish Trend 16 days ago
79%
Bearish Trend 16 days ago
84%
View a ticker or compare two or three
Ad is loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DIN29.940.84
+2.89%
Dine Brands Global
BFH65.071.32
+2.07%
Bread Financial Holdings
KGC10.64N/A
N/A
Kinross Gold Corp
SHEL65.95-0.82
-1.23%
Shell plc
SKIL29.54-2.54
-7.92%
Skillsoft Corp

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with KANT. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then KANT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
+5.74%
KANT - MDGL
62%
Loosely correlated
N/A
VXRT - MDGL
61%
Loosely correlated
+6.89%
ALXO - MDGL
56%
Loosely correlated
+9.09%
REPL - MDGL
55%
Loosely correlated
+9.87%
ZNTL - MDGL
51%
Loosely correlated
+0.44%
More